TY - JOUR
T1 - Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective
T2 - pan European patient survey
AU - Canonica, G Walter
AU - Klimek, Ludger
AU - Acaster, Sarah
AU - Dollner, Ralph
AU - Kaulsay, Ranbir
AU - Lo, Siu Hing
AU - Price, David B
AU - Scadding, Glenis K
AU - Valovirta, Erkka
AU - Zieglmayer, Petra
N1 - Funding Information:
Funding for this research was provided by Mylan Inc.
Funding Information:
PZ : has received lecture fees from Alk Abello, Allergopharma, Allergy Therapeutics, HAL, Leti, Meda, Merck, Novartis, Stallergenes, Thermo Fisher Scientific, scientific and educational grants from Alk Abello, Allergopharma, Allergy Therapeutics, Biomay, Calistoga, GSK, HAL, Marinomed, MSD, Ono, Oxagen, RespiVert, Stallergenes, VentirX, and is board member of Alk Abello, Bencard, Meda, Merck, Novartis, Sigmapharm, and Stallergenes.
Funding Information:
RD : has received research grants from Hal Allergy, Thermo Fisher, and Meda; payment for travel/accommodation/meeting expenses as well as lecture fees from Allergy Therapeutics, GSK, Thermo Fisher, Hal Allergy, and Meda.
Funding Information:
RK : Has received research grants from MEDA & Mylan and lecture and travel grants from MEDA, A. Menarini, GSK, Stallergenes, ALK Abello, Schering Plough, UCB Pharma, and Novartis.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021/7
Y1 - 2021/7
N2 - OBJECTIVE: The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients' lives and (3) explore factors associated with treatment satisfaction.METHODS: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March-June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-9; max score = 100). Participants (aged ≥18 years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.RESULTS: Pre-MP-AzeFlu treatment, participants (n = 1004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of participants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and ≥70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.CONCLUSIONS: The impact of AR on patients' lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.
AB - OBJECTIVE: The aims of this survey were to (1) assess the burden of allergic rhinitis (AR) from the patient perspective, (2) investigate MP-AzeFlu use in real life and its impact on patients' lives and (3) explore factors associated with treatment satisfaction.METHODS: A cross-sectional, quantitative, online, questionnaire-based survey was conducted in seven European countries (March-June 2019). Questions explored AR burden and treatment satisfaction. Satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication 9-item (TSQM-9; max score = 100). Participants (aged ≥18 years) had a doctor/healthcare provider confirmed AR diagnosis and used MP-AzeFlu within the last year.RESULTS: Pre-MP-AzeFlu treatment, participants (n = 1004) reported an average of 3.3 (SD:3.5) doctor visits/year, 8.1 (SD:11.0) days/year absenteeism and 15.8 (SD:18.9) days/year presenteeism due to AR. Only 48% of participants used MP-AzeFlu twice/day as recommended. Post-MP-AzeFlu 57% of participants reported better QoL, 47% reported fewer doctor visits and 52% discontinued polypharmacy. Absenteeism and presenteeism were reduced by 2.5 (SD 10.0) and 7.3 (SD:16.0) days/year, respectively. 70% of participants were more/much more satisfied with MP-AzeFlu versus previous AR treatment(s), and ≥70% were satisfied/extremely satisfied with its ability to prevent/treat AR, relieve symptoms and with its onset of action. Mean global, effectiveness and convenience TSQM-9 scores were 70.0 (SD:19.8), 68.3 (SD:21.6) and 72.7 (SD:20.4), respectively. Treatment satisfaction and effectiveness were significantly improved when MP-AzeFlu was taken as recommended.CONCLUSIONS: The impact of AR on patients' lives remains high. Real-life use of MP-AzeFlu reduces that impact and is associated with a high level of effectiveness, convenience and global satisfaction.
KW - Cross-Sectional Studies
KW - Fluticasone
KW - Humans
KW - Phthalazines
KW - Quality of Life
KW - Rhinitis, Allergic/drug therapy
KW - Surveys and Questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85104693655&partnerID=8YFLogxK
U2 - 10.1080/03007995.2021.1911973
DO - 10.1080/03007995.2021.1911973
M3 - Journal article
C2 - 33840316
SN - 0300-7995
VL - 37
SP - 1259
EP - 1272
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 7
ER -